Investing.com - Genmab AS reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Genmab AS announced earnings per share of $0.2682 on revenue of $255.24M. Analysts polled by Investing.com anticipated EPS of $0.0457 on revenue of $220.2M.
Genmab AS shares are down 9% from the beginning of the year and are trading at $36.68 , down-from-52-week-high.They are under-performing the STOXX 600 which is up 10.65% from the start of the year.
Genmab AS follows other major sector earnings this month
Genmab AS's report follows an earnings beat by Industrial Commercial Bank of China on Thursday, April 29, 2021, who reported EPS of $0.7417 on revenue of $33.09B, compared to forecasts EPS of $0.6343 on revenue of $34.72B.
L’Oreal ADR had matched expectations on Thursday, April 15, 2021 with first quarter EPS of $1.03 on revenue of $9.12B, compared to forecast for EPS of $1.03 on revenue of $9.23B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar